Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

​AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Could Skyrocket in 2026. Wall Street is bullish on the stock as all 14 analysts covering the stock maintain a Buy rating, and their 12-month average price target suggests more than 280% upside from the current level.

​Recently, on June 8, H.C. Wainwright reiterated its Buy rating and $25 price target on AtaiBeckley Inc. (NASDAQ:ATAI). The rating comes after the firm met the company’s management on June 2. The discussion reinforced the firm’s conviction that BPL-003, which is an intranasal formulation of 5-MeO-DMT, remains the primary driver for the company. Moreover, management told the firm that they are preparing to launch their Phase 3 program, called ReConnection, targeting treatment-resistant depression.

​H.C. Wainwright highlighted several practical advantages of BPL-003’s profile, including an 8 mg dose that balances efficacy and tolerability, a short in-clinic session duration, flexible retreatment options, and clinic economics that fit neatly into a two-hour interventional psychiatry model. The firm believes that these positive points make it operationally attractive for treatment centers.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1